Anhedonia and depression severity measures during ketamine administration in treatment-resistant depression.

"Conflict of interest AK has received research support from GH Research, MSD, Novartis. AW has received research support: KCR, Janssen, Otsuka, Apodemus, Novartis, Cortexyme, GH Research and Acadia. WJC has received grants from Acadia, Angelini, Celon, Cortexyme, GH Research, HMNC Brain Health, IntraCellular Therapies, Janssen, MSD, Novartis, Otsuka; he has received honoraria from Angelini, Celon, Janssen, Novartis, Sanofi; he serves on advisory boards in Angelini, Celon terminated, Douglas Pharmaceuticals, Janssen, MSD, Novartis, Sanofi."

"The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Funding for this study was provided by Medical University of Gdańsk grant number 01-10024/0006051/01/221/221/0/2024; the funder had no further role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication."

"This is a post-hoc analysis of the GDKet study cohort, involving individuals from an intravenous (i.v.) ketamine treatment registry for TRD. Patients were recruited from tertiary medical center. The study’s population and methodology are detailed elsewhere (). It diagnosed participants according to DSM-5 criteria, focusing on TRD defined by inadequate response to ≥2 antidepressants at proper doses and duration. The study enrolled adult inpatients with TRD suitable for short-term i.v. ketamine treatment. It was registered at ClinicalTrials.gov (NCT04226963) and approved by the Independent Bioethics Committee for Scientific Research at Medical University of Gdańsk, Poland (NKBBN/172-674/2019). Patients gave written informed consent for participation and data use."